National Institutes of Health Clinical Center (CC): Melanoma trials

The registry lists 15 Melanoma studies with National Institutes of Health Clinical Center (CC) as lead sponsor. 0 are open to participants now and 5 have results posted.

Early Phase 1 1Phase 1 6Phase 2 10(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating LymphocytesTerminatedNCT01236573Phase 1/2Results posted
• Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic CancerTerminatedNCT00704938Phase 2Results posted
• Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the BrainTerminatedNCT00550654Phase 2Results posted
• Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye MelanomaTerminatedNCT00482911Phase 2Results posted
• Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic MelanomaCompletedNCT00096382Phase 2Results posted
• Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting BeadsTerminatedNCT01336985Phase 1
• Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic CancerCompletedNCT00436410Early Phase 1
• Positron Emission Tomography and CT Scan in Predicting Response in Patients With Metastatic Melanoma or Kidney Cancer Who Are Undergoing Cellular Adoptive Immunotherapy on a Surgery Branch Clinical TrialCompletedNCT00316901Phase 2
• LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By SurgeryCompletedNCT00295958Phase 2
• Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and Interleukin-2 in Treating Patients With Refractory or Recurrent Metastatic MelanomaTerminatedNCT00138229Phase 2
• Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic MelanomaCompletedNCT00091104Phase 1
• Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic MelanomaCompletedNCT00085462Phase 1
• Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV MelanomaCompletedNCT00077532Phase 2
• Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic MelanomaCompletedNCT00062036Phase 1/2
• Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory LymphomasCompletedNCT00019019Phase 1